CAS: 1699717-32-2

BAY-545

BAY-545 is a small molecule inhibitor, which is synthetically developed with precise activity targeting cyclin-dependent kinases (CDKs). It serves as a critical advancement in understanding the pharmacological modulation of key regulatory proteins involved in cell cycle progression. BAY-545 exerts its effects by selectively inhibiting specific CDKs, thereby altering the phosphorylation status of downstream targets. This inhibition disrupts the cell cycle, leading to cell cycle arrest and potentially inducing apoptosis in cancerous cells. The applications of BAY-545 are primarily in cancer research, where it is used to study the effects of CDK inhibition on tumor proliferation. By understanding the molecular mechanisms by which BAY-545 acts, researchers can explore its potential as a therapeutic option for various malignancies. Its use extends into biochemical assays aimed at elucidating the role of cell cycle regulators in oncology, offering insights that may lead to the development of novel cancer treatment strategies.

BAY-545 is an antagonist of A2B adenosine receptor(IC50 : 59 nM).